DNMT1 and cancer: In this study, we designed a novel type of EpC nanocarrier to improve the response of epi-drugs towards aberrant DNA methylation by simultaneously delivering a DNMT inhibitor and the pDNA of the TET gene into cancer cells using a core–shell-type EpC nanocarrier strategy.